Premenstrual Syndrome and Premenstrual Dysphoric Disorder: Common Questions and Answers.
Level 5 - mechanism / opinion, no new human data
Narrative clinical review and expert practice guidance with no new empirical data or systematic search
What was done
This narrative clinical review summarizes common questions and practice recommendations regarding the clinical diagnosis, prospective symptom tracking, and management of premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD).
What was found
No quantitative findings or effect sizes are reported in the abstract. The review states that diagnosis requires prospective daily symptom tracking over at least two menstrual cycles (such as via the Daily Record of Severity of Problems). Selective serotonin reuptake inhibitors (SSRIs) represent first-line pharmacotherapy with rapid onset of symptom relief. Cognitive behavioral therapy, exercise, acupuncture or acupressure, and Vitex agnus-castus are identified as non-pharmacological or complementary therapeutic options.
Why it matters
It provides practical primary-care guidance for differentiating PMS from PMDD and implementing step-wise pharmacological and non-pharmacological interventions.
Limits
The abstract reports no original human subject data, sample sizes, or quantitative outcome measures. As a narrative review, it lacks a systematic search protocol and risk-of-bias evaluation for the cited interventions.